Cargando…
Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up
A retrospective study was performed to assess the histopathologic findings in high-risk women undergoing bilateral prophylactic (salpingo)-oophorectomy. The medical files of BRCA1 or BRCA2 mutation carriers and members of a hereditary breast/ovarian cancer (HBOC) family, who had undergone prophylact...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409718/ https://www.ncbi.nlm.nih.gov/pubmed/15083174 http://dx.doi.org/10.1038/sj.bjc.6601692 |
_version_ | 1782155842313781248 |
---|---|
author | Olivier, R I van Beurden, M Lubsen, M A C Rookus, M A Mooij, T M van de Vijver, M J van't Veer, L J |
author_facet | Olivier, R I van Beurden, M Lubsen, M A C Rookus, M A Mooij, T M van de Vijver, M J van't Veer, L J |
author_sort | Olivier, R I |
collection | PubMed |
description | A retrospective study was performed to assess the histopathologic findings in high-risk women undergoing bilateral prophylactic (salpingo)-oophorectomy. The medical files of BRCA1 or BRCA2 mutation carriers and members of a hereditary breast/ovarian cancer (HBOC) family, who had undergone prophylactic surgery, were reviewed. In all, 38 women underwent a bilateral oophorectomy (26 BRCA1, three BRCA2 and nine HBOC, respectively). A total of 90 women underwent bilateral salpingo-oophorectomy (58 BRCA1, six BRCA2, one BRCA1 and 2, 25 HBOC, respectively). At the time of salpingo-oophorectomy, five of 58 BRCA1 carriers (8.6%) were diagnosed with an occult carcinoma: two fallopian tube carcinomas, two ovarian carcinomas and one case was defined as a fallopian tube/ovarian carcinoma. No occult carcinomas were found in the other groups. Of the 38 patients, who underwent a bilateral oophorectomy (mean follow-up 45 months), three of 26 BRCA1 mutation carriers (3.4 in 100 women-years) developed peritoneal papillary serous carcinoma (PPSC) during follow-up. So far, no PPSC have occurred in the 90 women, who underwent a salpingo-oophorectomy (mean follow-up 12 months), including 58 BRCA1 carriers (0 in 60 in women-years). These results contribute to the thesis that BRCA1 germline mutation carriers are not only at risk for ovarian cancer, but also for fallopian tube carcinoma and peritoneal papillary serous carcinoma. Our data suggest that PPSC risk among BRCA2 carriers is lower than among BRCA1 carriers. |
format | Text |
id | pubmed-2409718 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2004 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-24097182009-09-10 Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up Olivier, R I van Beurden, M Lubsen, M A C Rookus, M A Mooij, T M van de Vijver, M J van't Veer, L J Br J Cancer Clinical A retrospective study was performed to assess the histopathologic findings in high-risk women undergoing bilateral prophylactic (salpingo)-oophorectomy. The medical files of BRCA1 or BRCA2 mutation carriers and members of a hereditary breast/ovarian cancer (HBOC) family, who had undergone prophylactic surgery, were reviewed. In all, 38 women underwent a bilateral oophorectomy (26 BRCA1, three BRCA2 and nine HBOC, respectively). A total of 90 women underwent bilateral salpingo-oophorectomy (58 BRCA1, six BRCA2, one BRCA1 and 2, 25 HBOC, respectively). At the time of salpingo-oophorectomy, five of 58 BRCA1 carriers (8.6%) were diagnosed with an occult carcinoma: two fallopian tube carcinomas, two ovarian carcinomas and one case was defined as a fallopian tube/ovarian carcinoma. No occult carcinomas were found in the other groups. Of the 38 patients, who underwent a bilateral oophorectomy (mean follow-up 45 months), three of 26 BRCA1 mutation carriers (3.4 in 100 women-years) developed peritoneal papillary serous carcinoma (PPSC) during follow-up. So far, no PPSC have occurred in the 90 women, who underwent a salpingo-oophorectomy (mean follow-up 12 months), including 58 BRCA1 carriers (0 in 60 in women-years). These results contribute to the thesis that BRCA1 germline mutation carriers are not only at risk for ovarian cancer, but also for fallopian tube carcinoma and peritoneal papillary serous carcinoma. Our data suggest that PPSC risk among BRCA2 carriers is lower than among BRCA1 carriers. Nature Publishing Group 2004-04-19 2004-03-16 /pmc/articles/PMC2409718/ /pubmed/15083174 http://dx.doi.org/10.1038/sj.bjc.6601692 Text en Copyright © 2004 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Clinical Olivier, R I van Beurden, M Lubsen, M A C Rookus, M A Mooij, T M van de Vijver, M J van't Veer, L J Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up |
title | Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up |
title_full | Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up |
title_fullStr | Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up |
title_full_unstemmed | Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up |
title_short | Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up |
title_sort | clinical outcome of prophylactic oophorectomy in brca1/brca2 mutation carriers and events during follow-up |
topic | Clinical |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409718/ https://www.ncbi.nlm.nih.gov/pubmed/15083174 http://dx.doi.org/10.1038/sj.bjc.6601692 |
work_keys_str_mv | AT olivierri clinicaloutcomeofprophylacticoophorectomyinbrca1brca2mutationcarriersandeventsduringfollowup AT vanbeurdenm clinicaloutcomeofprophylacticoophorectomyinbrca1brca2mutationcarriersandeventsduringfollowup AT lubsenmac clinicaloutcomeofprophylacticoophorectomyinbrca1brca2mutationcarriersandeventsduringfollowup AT rookusma clinicaloutcomeofprophylacticoophorectomyinbrca1brca2mutationcarriersandeventsduringfollowup AT mooijtm clinicaloutcomeofprophylacticoophorectomyinbrca1brca2mutationcarriersandeventsduringfollowup AT vandevijvermj clinicaloutcomeofprophylacticoophorectomyinbrca1brca2mutationcarriersandeventsduringfollowup AT vantveerlj clinicaloutcomeofprophylacticoophorectomyinbrca1brca2mutationcarriersandeventsduringfollowup |